AnaptysBio, Inc.
ANAB
$20.55
$1.497.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -145.23M | -165.66M | -170.12M | -163.30M | -163.62M |
| Total Depreciation and Amortization | 2.40M | 2.40M | 2.40M | 2.39M | 2.38M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 73.82M | 60.45M | 48.66M | 43.24M | 40.77M |
| Change in Net Operating Assets | -66.33M | -207.00K | -10.34M | -15.82M | -324.00K |
| Cash from Operations | -135.34M | -103.01M | -129.40M | -133.49M | -120.80M |
| Capital Expenditure | -358.00K | -375.00K | -502.00K | -659.00K | -807.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.76M | 174.35M | 146.49M | 128.63M | 145.56M |
| Cash from Investing | 95.40M | 173.97M | 145.99M | 127.97M | 144.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 100.84M | 100.55M | 2.21M | 2.02M | 2.47M |
| Repurchase of Common Stock | -456.00K | 0.00 | 0.00 | -12.47M | -50.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 26.67M | -6.22M | 17.81M | -24.90M | -11.77M |
| Cash from Financing | 127.05M | 94.33M | 20.03M | -35.36M | -59.30M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.12M | 165.29M | 36.62M | -40.87M | -35.34M |